IR Biosciences Holdings, Inc.
IRBS
$0.00
$0.000.00%
OTC PK
| 12/31/2010 | 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -44.10% | -54.08% | 49.61% | 5.31% | -46.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.10% | -54.08% | 49.61% | 5.31% | -46.91% |
| Operating Income | 44.10% | 54.08% | -49.61% | -5.31% | 46.91% |
| Income Before Tax | -146.96% | 7.61% | 158.24% | -55.36% | 143.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -146.96% | 7.74% | 158.24% | -55.36% | 143.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -146.96% | 7.74% | 158.24% | -55.36% | 143.57% |
| EBIT | 44.10% | 54.08% | -49.61% | -5.31% | 46.91% |
| EBITDA | 44.14% | 54.14% | -49.76% | -5.73% | 46.94% |
| EPS Basic | -124.36% | 21.30% | 149.84% | -45.80% | 139.91% |
| Normalized Basic EPS | 46.96% | 65.22% | -6.81% | 7.70% | 27.41% |
| EPS Diluted | -124.36% | 21.30% | 149.84% | -45.80% | 139.91% |
| Normalized Diluted EPS | 46.96% | 65.22% | -6.81% | 7.70% | 27.41% |
| Average Basic Shares Outstanding | 27.72% | 27.50% | 16.88% | 6.52% | 9.12% |
| Average Diluted Shares Outstanding | 27.72% | 27.50% | 16.88% | 6.52% | 9.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |